Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › REDEFINE 1

REDEFINE 1

CagriSema · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
CagriSema
Population
obesity
Official title
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Sponsor
Novo Nordisk A/S
Phase
3
Registry status
active not recruiting · 2022-11 → 2024-10
Participants
3417
Duration
68 weeks
Registry
NCT05567796

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
CagriSema 2.4/2.4 mgobesity683417−22.7 % vs −2.3 %
Δ −20.4 pp
−20.4 % vs −3.0 %
Δ −17.4 pp
—5.9 vs 3.511.8 vs 24.1——9.8 vs 6.1−9.9 vs −3.2verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (6)
  • CagriSema 2.4/2.4 mg · weight_eff · Results, Efficacy, Body-Weight Reduction; Fig 1B
    On the basis of the trial-product estimand, the percent weight reduction was −22.7% with cagrilintide–semaglutide and −2.3% with placebo
  • CagriSema 2.4/2.4 mg · weight_tp · Table 2; Results, Efficacy
    the mean percent body-weight reduction at week 68 was −20.4% with cagrilintide–semaglutide and −3.0% with placebo
  • CagriSema 2.4/2.4 mg · ae_dc · Table 3; Results, Safety
    discontinued because of adverse events (5.9% vs. 3.6%, 2.6%, and 3.5%, respectively)
  • CagriSema 2.4/2.4 mg · sae · Table 3; Results, Safety
    Serious adverse events were reported in 9.8% of the participants receiving cagrilintide–semaglutide
  • CagriSema 2.4/2.4 mg · sbp · Table 2; Results, Additional End Points
    The mean reduction from baseline to week 68 in systolic blood pressure was −9.9 mm Hg with cagrilintide–semaglutide and −3.2 mm Hg with placebo
  • CagriSema 2.4/2.4 mg · disc_any · Results, Participants
    The percentage of participants still receiving the drug or placebo at week 68 was 88.2% in the cagrilintide–semaglutide group, 91.4% in the semaglutide group, 87.7% in the cagrilintide group, and 75.9% in the placebo gro

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: REDEFINE 1. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/redefine-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.